Pathogenetic effects of low-intensity laser therapy for chronic obstructive pulmonary disease

Аксенова, И З; Burduli, N M

doi:10.17116/terarkh201688332-35

Cited by 7 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It will be a wise investment to urgently investigate these initial results clinically, and not wait for another deadly coronavirus pandemic to remind us of the inherent potential of light as a therapeutic tool. The urgency of this call is heightened by recent clinical results, which indicate that patients with chronic obstructive lung disease and others with bronchial asthma and allergy improved significantly following treatment with light [91,92].…”

Section: Photobiomodulation and Acute Pulmonary Disordermentioning

confidence: 99%

Light as a potential treatment for pandemic coronavirus infections: A perspective

Enwemeka

Bumah

Masson-Meyers

2020

Journal of Photochemistry and Photobiology B: Biology

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Section: Photobiomodulation and Acute Pulmonary Disordermentioning

confidence: 99%

Light as a potential treatment for pandemic coronavirus infections: A perspective

Enwemeka

Bumah

Masson-Meyers

2020

Journal of Photochemistry and Photobiology B: Biology

View full text Add to dashboard Cite

show abstract

“…207 This statement is supported by the evidence-based clinical results, which showed a significant improvement in patients with chronic obstructive pulmonary syndrome (COPD) and asthma following PBMT. 208,209 Figure 3 illustrates the mechanism in which PBM can reverse the cellular and molecular activities of the SARS-CoV-2 virus. 200,203,206 On this note, the first severe case of COVID-19 pneumonia treated with PBMT, as an adjunct to standard conventional protocol was recently treated by Sigman et al, which aimed to reduce inflammation and promote lung healing.…”

Section: Future Noninvasive Therapymentioning

confidence: 99%

Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review

Hanna¹,

Dalvi²,

Sălăgean³

et al. 2021

JIR

View full text Add to dashboard Cite

“…Chronic obstructive pulmonary disease (COPD), also known as obstructive emphysema, can further develop into common chronic diseases of pulmonary heart disease and respiratory failure 1 , 2 . Recently, the incidence rate of COPD has increased significantly due to air pollution, smoking and chronic bronchitis 3 . The symptoms of COPD cause a huge global burden of respiratory diseases 4 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease

Yang

Huang

Tian

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The most classic treatment recommended in the current chronic obstructive pulmonary disease (COPD) guidelines is glucocorticoid and β2 receptor agonist combination, such as salmeterol xinafoate and fluticasone propionate (Sal/Flu), causing many adverse reactions due to hormones. Magnesium isoglycyrrhizinate (MgIG) is an anti-inflammatory glycyrrhizic acid preparation for treating chronic inflammation, contributing to its structure is similar to steroidal anti-inflammatory drugs. In this study, we successfully established COPD rat model by endotracheal-atomized lipopolysaccharide exposure and cigarette smoke induction, as characterized by lung function decline. We discovered that salmeterol xinafoate/MgIG combination could alleviated lung inflammation infiltration, airway wall thickness (AWT) and the secretion of bronchial mucin MUC5AC of COPD rats more than salmeterol xinafoate, MgIG, or salmeterol xinafoate and fluticasone propionate treatment did, as well as reduced inflammatory cells (white blood cells, neutrophils and lymphocytes) accumulation in bronchoalveolar lavage fluid and decreased TNF-α, IL-6 and IL-1β production in the serum of COPD rats. Finally, we found that Moreover, the mechanism involved might be related to the suppression of JAK/STAT signaling pathway. Overall, our studies suggested that MgIG might be a potential alternative adjuvant drug for fluticasone propionate for the clinical treatment of patients with COPD.

show abstract

Pathogenetic effects of low-intensity laser therapy for chronic obstructive pulmonary disease

Abstract: Laser therapy used in the combination treatment of patients with COPD promotes correction of the typical pathological processes.

Cited by 7 publications

References 1 publication

Light as a potential treatment for pandemic coronavirus infections: A perspective

Light as a potential treatment for pandemic coronavirus infections: A perspective

Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review

Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About